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Abstract 
HNF1A/HNF4A maturity onset diabetes of the young (MODY) and KATP channel neonatal 
diabetes (NDM) are optimally treated with sulfonylureas outside pregnancy, but there is 
little evidence regarding the most appropriate treatment during pregnancy.  
Glibenclamide has been widely used in the treatment of gestational diabetes, however 
recent data establishes that glibenclamide crosses the placenta, and increases risk of 
macrosomia and neonatal hypoglycaemia. This raises questions about its use in pregnancy.    
We review the available evidence and make recommendations for the management of 
monogenic diabetes in pregnancy. 
Due to the risk of stimulating increased insulin secretion in utero, we recommend that in 
women with HNF1A/ HNF4A MODY, those with good glycaemic control on a sulfonylurea 
pre-conception either transfer to insulin before conception [at the risk of a short-term 
deterioration of glycaemic control] or continue with sulfonylurea (glibenclamide) treatment 
in the first trimester and transfer to insulin in the second trimester.  Early delivery is needed 
if the fetus inherits an HNF4A mutation from either parent as increased insulin secretion 
results in ~800g weight gain in utero, and prolonged severe neonatal hypoglycaemia can 
occur post-delivery. 
If the fetus inherits a KATP neonatal diabetes mutation from their mother they have greatly 
reduced insulin secretion in utero that reduces fetal growth by approximately 900g. Treating 
the mother with glibenclamide in the third trimester treats the affected fetus in utero 
normalising fetal growth but is not desirable, especially in the high doses used in this 
condition, if the fetus is unaffected.   
Prospective studies of pregnancy in monogenic diabetes are needed. 
 
 
 
What this review adds 
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 Recent data shows glibenclamide crosses the placenta and its use in pregnancy is 
associated with increased birth weight and neonatal hypoglycaemia. This has 
implications for the treatment of pregnant women with monogenic diabetes whose 
diabetes is usually well controlled with sulfonylureas.  
 
 Optimal management of HNF1A /HNF4A MODY in pregnancy requires excellent 
glycaemic control in the first trimester to minimise the risk of fetal malformations 
whilst avoiding the negative impact of glibenclamide on fetal weight gain in the third 
trimester. 
 
 In mothers with KATP neonatal diabetes, glibenclamide treatment in pregnancy can 
be beneficial if the fetus is affected, as restoration of fetal KATP function will result in 
improved fetal growth.  
 
 If the genotype of the fetus is unknown, when a parent has KATP neonatal diabetes or 
HNF4A MODY, serial antenatal ultrasound assessment of fetal growth may be used 
as a proxy to aid management decisions. 
 
 Management of monogenic diabetes during pregnancy could be revolutionised in 
the future by testing cell-free fetal DNA in the mother.   
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Background 
The recognition of monogenic diabetes is important as it allows improvement of therapy.  
For several subtypes of monogenic diabetes, insulin treatment or other glucose lowering 
medication can be replaced by sulfonylureas.  The common subtypes of maturity onset 
diabetes of the young (MODY) due to mutations in HNF1A and HNF4A are optimally treated 
with low dose sulfonylureas [1,2] and the commonest subtypes of permanent neonatal 
diabetes due to KCNJ11 or ABCC8 mutations can achieve excellent glycaemic control with 
high dose sulfonylureas [3-5].   
How should sulfonylurea-treated monogenic diabetes be managed in pregnancy?  The 
sulfonylurea most widely use in pregnancy is glibenclamide.  Until recently it was believed 
that transfer across the placenta was minimal. However evidence from its use in gestational 
diabetes mellitus (GDM) now clearly demonstrates that glibenclamide crosses the placenta 
[6,7] and stimulates fetal insulin secretion, resulting in increased fetal growth and increased 
rates of neonatal hypoglycaemia [8-10].  
In monogenic diabetes the situation is more complex as there are specific considerations in 
addition to concern about maternal glycaemia - these include the sulfonylurea doses 
required, the fetal mutation status and the desirability of exposure to sulfonylureas that 
differ across the specific genetic subtypes. 
In this review we discuss first the evidence for use of glibenclamide in pregnancies in 
mothers who do not have monogenic diabetes.  We then consider the three common 
subtypes of sulfonylurea-treated monogenic diabetes, HNF1A/4A MODY and KCNJ11/ABCC8 
permanent neonatal diabetes.  We outline sulfonylurea treatment outside pregnancy in 
these conditions and review the evidence for treatment and outcome in pregnancy.  We 
also suggest a practical approach given the paucity of evidence available. 
Literature search 
A systematic literature review was undertaken using PubMed, Embase and OVID.  Keywords 
included: monogenic diabetes, MODY, HNF1A, HNF4A, potassium channel (KATP) neonatal 
diabetes mellitus (KCNJ11 and ABCC8), pregnancy, glibenclamide or glyburide, and 
gestational diabetes. 
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Sulfonylurea treatment in pregnancy in Type 2 diabetes and gestational diabetes – a 
changing landscape 
Data on the use of glibenclamide in pregnancy consist of more than 9500 exposures, mainly 
in late pregnancy in women with gestational diabetes [11]. Glibenclamide has until recently 
been considered a safe drug to use in pregnancy.  In vitro studies suggested that transfer 
across the placenta was minimal [12-14] and glibenclamide was undetectable in cord blood 
[15].  Early clinical studies suggested there was no significant increase in macrosomia or 
neonatal hypoglycaemia compared to insulin use [15-20] but these studies were limited in 
their power to demonstrate differences [21]. In a meta-analysis (10 studies on 471 women 
exposed women to sulfonylureas and biguanides in first trimester), no significant difference 
was found in the rate of major malformations or neonatal death among women with 
exposure to oral anti-diabetic agents in the first trimester compared with non-exposed 
women, but the meta-analysis was limited by study heterogeneity [22].  In one study of 379 
pregnancies there was a significant increase in perinatal mortality (125/1000 births v 
33/1000 births) and stillbirth with oral glucose lowering agents compared to those treated 
with insulin (91/1000 births v 33/1000 births, p<0.05) but the authors concluded that early 
exposure to these agents was unlikely to be deleterious [23]. 
Subsequent studies, using more sensitive assays, have confirmed that glibenclamide does 
cross the placenta, with umbilical cord plasma concentrations averaging 70% of maternal 
values [24].  More recent publications have demonstrated an increased risk of obstetric and 
neonatal complications with sulphonylurea use. Even though good glycaemic control may be 
maintained, pregnant women with GDM treated with glibenclamide had bigger babies than 
insulin-treated mothers, further increasing the risk of obstetric and neonatal complications 
from macrosomia [25,26].  In a meta-analysis of randomized controlled trials glibenclamide 
use resulted in increased in birth weight, mean difference 109g, (confidence interval 36 to 
181), macrosomia, risk ratio (RR) 2.62 (1.35-5.08) and fetal hypoglycaemia, RR 2.04 (1.30 to 
3.20) [10]. In a large USA cohort study of 110,000 women with GDM, newborns of women 
treated with glibenclamide (glyburide) were at increased risk for neonatal intensive care 
unit admission (RR = 1.41; 95% CI, 1.23-1.62), respiratory distress (RR = 1.63; 95% CI, 1.23-
2.15), hypoglycemia (RR = 1.40; 95% CI, 1.00-1.95), birth injury (RR = 1.35; 95% CI, 1.00-
1.82), and large for gestational age (RR = 1.43; 95% CI, 1.16-1.76) compared with those 
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treated with insulin [26]. An additional study of 2073 women also found higher odds of  
neonatal intensive care admission (aOR 1.46, 1.07-2.00) and birthweight >4000g (aOR=1.29 
[1.03-1.64]) amongst infants born to mothers receiving glibenclamide during pregnancy  
[27].  The vidence now indicates that glibenclamide treatment in the third trimester 
exacerbates fetal hyperinsulinism in utero and has an additive effect on birth weight [10,26, 
28]. These studies have raised concern regarding the use of glibenclamide in pregnancy [25]. 
There is limited experience of sulfonylurea use in the first trimester, the data that exists, 
suggest they are not teratogenic when used at conception or in the first trimester 
[22,23,29], though maternal glycated haemoglobin was independently associated with 
congenital anomalies [30]. However many studies group those on different oral agents 
together, so data for specific sulfonylureas, and in particular glibenclamide, are not 
available. As there are extremely limited data on other sulfonylureas, and they are not 
recommended in pregnancy, they are not considered in this review.  
 
Current recommendations for the use of glibenclamide in pregnancy now reflect the 
concerns that have arisen from the recent studies. Glibenclamide is not recommended in 
GDM if insulin or metformin is available [10, 31]. In women with Type 2 diabetes it is 
recommended that oral antidiabetic agents (other than metformin) are discontinued before 
pregnancy, and insulin substituted [31]. The United Kingdom Teratology Information Service 
(UKTIS) advises, in the absence of evidence for teratogenicity, that glibenclamide may be 
considered in pregnancy where clinically indicated [11]; this could include KATP neonatal 
diabetes and HNF1A / HNF4A MODY where excellent glycaemic control can be achieved on 
sulfonylureas. Glibenclamide can be resumed post-delivery and during breast-feeding for 
those with pre-existing diabetes [32].   
 
Current opinion suggests that glibenclamide is not teratogenic, and that it is probably safe in 
the first trimester. Its use in later pregnancy is a cause for concern, with an increase in 
adverse fetal outcomes reported, in particular fetal growth and neonatal hypoglycaemia.   
 
What are the specific issues for sulfonylurea-treated monogenic diabetes in pregnancy ? 
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Individuals with HNF1A MODY, HNF4A MODY and KCNJ11/ABCC8 permanent neonatal 
diabetes can achieve excellent control on sulfonylureas outside pregnancy, and glycaemic 
control may be better on sulfonylureas than insulin [1-5]. However, given that glibenclamide 
treatment increases the risk of macrosomia and neonatal hypoglycaemia, its use in 
monogenic diabetes pregnancy needs to be reconsidered. 
These conditions are dominantly-inherited, so there is a 50% chance of each fetus inheriting 
the mutation from their affected parent. Sulfonylureas crossing the placenta may be 
beneficial or detrimental depending on fetal genotype, but in the majority of cases the fetal 
genetic status will be unknown, making management more complicated. 
Treatment decisions need to consider many factors including monogenic subtype, pre-
pregnancy glycaemic control and treatment, gestation, patient preference, fetal growth and 
fetal inheritance status (if known). Optimal glycaemic control is essential during 
organogenesis, and fetal growth is an important consideration with advancing gestation 
(Figure 1). Decisions regarding pregnancy management are, of course, individual and should 
be made with multidisciplinary input involving the patient, diabetologists and obstetricians.  
As there are different issues to consider within the three subtypes we will discuss each 
separately. 
Monogenic diabetes pregnancy 
HNF1A MODY  
1. Optimum therapy outside pregnancy 
HNF1A MODY is optimally managed using low doses of sulfonylureas [1, 2, 33]. The 
mechanism for the increased glycaemic response to sulfonylureas seen in HNF1A MODY, 
compared with Type 2 diabetes, is thought to be due to increased pancreatic insulin 
secretory response to sulfonylureas and increased sensitivity to the insulin released [1]. 
2. Reports of pregnancy 
i) Impact of fetal genotype 
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The largest study of neonatal outcomes associated with monogenic diabetes found no 
difference in birth weight or rate of macrosomia in 134 infants inheriting HNF1A MODY 
mutations compared to their unaffected siblings (median birth weight 3490g) [34]. 
Mutations in HNF1A were not associated with an increased birth weight, with amedian 
difference of 10g and a mean difference in the analysis of 24 discordant sibling pairs (  of 3g.  
Neither the birth weight nor the incidence of hypoglycaemia in heterozygous HNF1A 
mutation carriers differed from their unaffected sibling, suggesting that fetal insulin 
secretion was not increased in HNF1A mutation carriers [34]. If the mother carried the 
mutation the birth weight was increased due to maternal hyperglycaemia but the increase 
was similar if the fetus was affected or unaffected.  Similar findings were identified in other 
cohorts [35].  A single reported case of neonatal hypoglycaemia in a HNF1A mutation carrier 
resolved within 48 hours [34]. Consequently inheritance of an HNF1A mutation is not 
considered to associated with adverse birth outcomes or obstetric morbidity.  
 
ii) Impact of maternal therapy in pregnancy 
There are no reports of the outcomes of sulfonylurea treatment in HNF1A MODY 
pregnancies, so the neonatal effects of sulfonylureas are not known.   
3. Recommendations  
There are two main treatment options (Figure 2): i) stop sulfonylureas pre-pregnancy and 
transfer to insulin or ii) treat with glibenclamide pre/early pregnancy and transfer to insulin 
in the second trimester.  The second option should only be considered if pre-pregnancy 
HbA1c reaches local targets for glycaemic control. The advantage of excellent glycaemic 
control at conception and in the first trimester needs to be balanced against the lack of 
sufficient safety data on glibenclamide in the first trimester and the need to transfer from 
glibenclamide before the third trimester. Using insulin prior to conception has the 
advantage that this treatment can be continued throughout pregnancy and has a proven 
safety record at all stages of pregnancy. However optimal glycaemic control at the time of 
conception and in the first trimester may be harder to achieve with insulin therapy.   
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If a woman taking sulfonylureas presents already pregnant, the benefit of transferring to 
insulin in early pregnancy needs to be weighed up against the potential deterioration in 
glycaemic control during organogenesis. In women with good glycaemic control, HbA1c 
<48mmol/mol (6.5%), on a sulfonylurea the deterioration in control on discontinuing a 
sulfonylurea can be marked and there is case for continuing with a sulfonylurea until the 
end of the first trimester. Those on an alternate sulfonylurea should be transferred to an 
equivalent dose of glibenclamide.  
If used before pregnancy and in the first trimester, glibenclamide should be discontinued 
before the third trimester, to avoid its trans-placental transfer. If this option is chosen, we 
suggest introducing a basal insulin in the second trimester and then replacing glibenclamide 
with bolus insulin as a second phase, aiming to achieve excellent glycaemic control well 
before week 26 of gestation. If glibenclamide is continued into the final trimester, doses 
should be as low as possible (≤5mg/day) as the impact on the fetus is likely to be dose-
related.   
We recommend that women with HNF1A MODY have the same fetal checks/scans as 
recommended for other pre-existing diabetes in pregnancy [31]. Delivery should be 
considered between 37 and 38+6 weeks in line with management of other pre-existing 
diabetes pregnancies [31]. Glibenclamide can be resumed post-delivery and during breast 
feeding, with transfer, if desired, to an alternative sulfonylurea after weaning.  
HNF4A MODY  
1.Optimum therapy outside pregnancy 
Low dose sulfonylureas are the optimal therapy in HNF4A MODY [2].  
2. Reports of pregnancy 
i) Impact of fetal genotype 
Inheritance of an HNF4A mutation results in a dramatic increase in birth weight. In a study 
of 108 individuals from HNF4A MODY families, babies inheriting an HNF4A mutation had a 
median birth weight 790g greater than their unaffected siblings (97th v 58th centile) [34]. 
There was an additional effect of maternal glycaemia; hence affected HNF4A infants born to 
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mothers with HNF4A MODY had a median corrected birthweight of 4840g compared to 
4170g when the father was affected [34]. The prevalence of macrosomia was 64% if the 
HNF4A mutation was inherited from the mother and 46% if it was inherited from the father. 
Extreme macrosomia (birthweight >5000g) was seen in 15% of cases with an affected 
mother and 7% of cases with an affected father [34]. The increase in birth weight when the 
mother is affected is likely to be due to the effects of maternal hyperglycaemia.  
The increased fetal growth associated with inheriting a fetal HNF4A mutation results in 
marked morbidity including neonatal hypoglycaemia, shoulder dystocia, brachial plexus 
birth injury, assisted delivery and emergency caesarean section [34, 36-39].  Infants born to 
a parent with HNF4A MODY require glucose monitoring after delivery as at least 10% of 
affected neonates have hypoglycaemia (blood glucose <2.5mmol/l)[34, 40]. Severe 
hyperinsulinaemic hypoglycaemia (blood glucose 0.8-2.5mmol/l for >24 hours) may require 
prolonged treatment (intravenous glucose infusion, glucagon and diazoxide / chlorthiazide) 
as the hypoglycaemia can persist for months or years [37,40, 41]. The increased birthweight 
and neonatal hypoglycaemia are a result of hyperinsulinism before and after birth [34]. The 
only exception is found in individuals with the p.R114W mutation which is atypical of HNF4A 
MODY in that it has no effect on birth weight [42]. 
ii) Impact of maternal therapy in pregnancy  
Reports of maternal treatment during pregnancy in HNF4A MODY are scarce.  In one case, 
insulin treatment did not prevent macrosomia or hypoglycaemia  [38].  The published data is 
inadequate to determine if there is an effect of sulfonylurea use. 
 
3. Recommendations 
As there is a very high risk of macrosomia in HNF4A pregnancies if the fetus is affected, 
achieving excellent glycaemic control is essential. 
 
The two main treatment options (Figure 2) are the same as those for HNF1A pregnancies as 
discussed above.  Additional information specific to HNF4A pregnancies is detailed below.   
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In women with HNF4A MODY serial growth assessment should be undertaken from 28 
weeks, on at least 2 weekly intervals depending on growth trajectory, in addition to routine 
anomaly screening at earlier gestation as advised by NICE, to detect developing macrosomia 
in affected fetuses. Early delivery is needed even with excellent glucose control if the fetus 
is genetically affected.  Induction of labour or elective caesarean section, should be 
considered from 35-38 weeks, based on estimated fetal size on ultrasound. A paediatrician 
should be available at delivery. Post-delivery the infant should be monitored for neonatal 
hypoglycaemia and for at least 48 hours, as this may be prolonged and need continued 
treatment. The mother can resume glibenclamide post-delivery and during breast feeding, 
with transfer to an alternative sulfonylurea, if desired, once breast feeding is completed. ' 
 
Management of pregnancies when the father has HNF4A MODY  
  
A fetus inheriting the HNF4A mutation from the father has a similar risk of macrosomia and 
its complications (shoulder dystocia, obstructed birth etc) as with maternal inheritance 
(median corrected birth weight 4200g)[34]. In addition there is a high risk of fetal 
hypoglycaemia that may be severe and profound (see above). Therefore we recommend 
regular ultrasound monitoring from 28 weeks gestation when the father has HNF4A MODY.  
If there is evidence of fetal macrosomia on scan early delivery (37-38+6 weeks) should be 
considered.  A paediatrician should review the child soon after birth and assess for 
hypoglycaemia (see recommendations above).  
KATP neonatal diabetes  
1.Optimum therapy outside pregnancy 
The vast majority of individuals with KCNJ11 or ABCC8 permanent neonatal diabetes are 
successfully managed with glibenclamide with improvements in HbA1c and no increase in 
hypoglycaemia [3, 4, 43].  The key difference in sulfonylurea treatment in neonatal diabetes 
is the high dose of glibenclamide required (0.45mg/kg/day) [3] compared to the low doses 
in HNF1A / HNF4A MODY (<0.01mg/kg/day) [1, 2] or typical doses in Type 2 diabetes (0.06-
0.2mg/kg/day) [32]. 
2. Reports of pregnancy 
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i) Impact of fetal genotype 
In KATP NDM pregnancies neonatal birth weight is dependent on fetal genotype. If the fetus 
has inherited the genetic mutation from either the mother or father, reduced fetal insulin 
secretion results in low birth weight, (median 2580g at median 39 weeks’ gestation) [44-46].  
 
ii) Impact of maternal therapy in pregnancy   
Glibenclamide treatment may be beneficial or detrimental depending on whether or not the 
fetus is affected. Three women with KCNJ11 mutations who were treated with a 
sulfonylurea during four pregnancies have been described.  The glibenclamide doses ranged 
from 2.8-90 mg/day [47-49]. If the fetus is unaffected then maternal use of high dose 
glibenclamide leads to high fetal doses, excess fetal insulin secretion, excess insulin-
mediated growth and neonatal hypoglycaemia [47-49]. In contrast when the fetus is 
affected, trans-placental transfer of sulfonylurea restores fetal KATP function and improves 
fetal growth, resulting in normal birth weight (median 3010g at 38 weeks) [47]. Interestingly 
one of the children described has not presented with NDM in the first 18 months of life [47]. 
Whether this is a legacy effect of the high dose glibenclamide or a mutation effect (the 
E229K mutation causes transient neonatal diabetes) [47] is not clear. 
Offspring (n=6) who inherited a KCNJ11 mutation from their affected insulin-treated 
mothers had a normal birth weight. In contrast, if the baby was born to a non-diabetic 
mother birth weight was reduced (–0.12 v –1.81 SD for birth weight) [45]. This suggests that 
maternal hyperglycaemia can lead to increased  fetal growth, even when there is a fetal 
mutation greatly reducing fetal insulin secretion. 
Breastfeeding 
In one mother with KCNJ11 neonatal diabetes taking very high doses of glibenclamide (90 
mg a day), persistent postnatal exposure led to hypoglycaemia in her unaffected neonate 
through transfer of the drug in breast milk [48].  However the doses of glibenclamide 
typically used in Type 2 diabetes are considered safe for breast feeding [32], 
3. Recommendations 
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The majority of women with KATP neonatal diabetes will already be treated with 
glibenclamide pre-pregnancy and excellent glycaemic control can usually be achieved 
(typically <48mmol/mol, 6.5%). If it is decided to continue sulfonylureas pre-conception and 
in the first trimester to aid glycaemic control then it is appropriate to reduce the 
glibenclamide dose to the lowest that maintains HbA1c ≤48mmol/mol (6.5%).  
If pregnancy is planned, transfer to insulin may be considered pre-conception but this will 
usually result in deterioration of glycaemic control with potential consequences on fetal 
outcome.  
The fetal genotype has a crucial role in determining whether glibenclamide therapy is 
recommended in KATP NDM. To determine if the fetus is affected, fetal genotyping should be 
offered if amniocentesis or chorionic villus sampling are being performed for another 
reason. Some authors have suggested that fetal genetic testing should be performed in all 
affected mothers, despite the risk (~1%) of miscarriage associated with invasive testing, as it 
would directly alter management [48,49]. If the fetal genotype is not tested directly, it may 
be possible to infer whether a fetus is likely to be affected by detecting reduced fetal growth 
by serial ultrasonography from 28 weeks gestation.  
If the fetus is affected, maternal glibenclamide treatment is appropriate when the mother 
has KATP  neonatal diabetes, as it will cross the placenta and provide in utero treatment of an 
affected fetus.  This improves both fetal growth and, potentially, brain development. If the 
fetus is thought to be affected glibenclamide should be continued at the lowest dose 
required for optimal glycaemic control.  If the mother had been transferred to insulin pre-
conception then glibenclamide should be reintroduced at the pre-pregnancy dose.   If the 
mutation has been inherited from an affected father, treatment with sulfonylurea during 
pregnancy is not possible.    
 
If the fetus is unaffected, or there is no ultrasound evidence that it is affected, glibenclamide 
in the last trimester will exacerbate excessive fetal growth and neonatal hypoglycaemia and 
so insulin is advised. However transfer to insulin will risk deterioration in glycaemic control 
at this time. Transfer from glibenclamide to insulin should be rapid (<3 days), a basal bolus 
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regimen should be introduced as the glibenclamide is stopped and rapidly titrated to 
achieve good glycaemic control. 
Timing of delivery should take into account the risk of continuing pregnancy in a suboptimal 
intrauterine growth environment versus that of prematurity from early intervention.  
Usually this will be between 37-38+6 weeks. 
A fetus inheriting a KATP mutation from its mother or father will usually present with 
diabetes before the age of 6 months and will have raised glucose before they present with 
ketoacidosis.  Prompt diagnosis and treatment is essential. A paediatrician should be 
available at delivery and the neonate’s blood glucose should be checked at birth and at least 
8 hourly for a minimum of 48 hours.  If the fetal genotype was not determined in pregnancy, 
rapid genetic testing of the fetus should be offered, as 50% of cases will be affected.  
Cord blood samples can be sent to the molecular genetics laboratory at the Royal Devon 
and Exeter NHS Foundation Trust (www.diabetesgenes.org) and will be tested as a priority, 
without charge.  Genetic test results in these cases should be available within a week of the 
arrival of the sample.  The initial treatment of neonatal diabetes should usually be insulin 
but sulfonylurea can be started as soon as the diagnosis is confirmed.   
After delivery, women with KATP neonatal diabetes can restart glibenclamide at pre-
pregnancy doses. The exception to this is when doses >0.2 mg/kg/day are used and breast 
feeding is planned. The transfer of the drug in breast milk may be significant at higher doses 
[48]. 
Antenatal testing for fetal genetic diagnosis 
Awareness of fetal genotype allows individualized obstetric care however fetal genotype is 
usually unknown, as at present it requires invasive testing. Due to the risks involved in 
chorionic villus sampling or amniocentesis, genetic testing is only usually considered 
antenatally if these tests are performed for another reason.  Fetal growth on 
ultrasonography may provide a surrogate of fetal inheritance in HNF4A MODY and KATP NDM 
in the absence of a confirmatory antenatal genetic test, and may be useful in guiding most 
appropriate management. Non-invasive genetic testing of cell free fetal DNA in maternal 
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blood is likely to revolutionize management of monogenic diabetes pregnancies in the 
future [50].   
 
Conclusions 
Glibenclamide is now known to cross the placenta and Its use in pregnancy can result in 
increased risk of large for gestational age infants, macrosomia and neonatal hypoglycaemia. 
The management of monogenic diabetes pregnancies that are treated with sulfonylureas 
outside pregnancy aims to achieve optimal glycaemic control during the first trimester 
whilst limiting the adverse effects of glibenclamide on fetal birthweight.  
 
We recommend avoiding glibenclamide use during the third trimester in women with 
HNF1A/HNF4A MODY. In KATP NDM glibenclamide can be continued throughout pregnancy if 
the fetus has reduced or low/normal fetal growth or is known to have inherited a KATP 
channel mutation. 
 
In the future, non-invasive pre-natal genetic testing will enable personalized management of 
HNF4A MODY and KATP NDM pregnancies. As data are currently lacking we advocate an 
international system of reporting all pregnancy management/outcomes in monogenic 
diabetes pregnancies to enable an evidence-based approach.  The monogenic diabetes team 
at the Royal Devon and Exeter NHS Foundation Trust would offer to act as a repository 
collating this information. 
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